This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Seale, H.
Right arrow Articles by Gilbert, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Seale, H.
Right arrow Articles by Gilbert, L.

Next Article 

Clinical and Vaccine Immunology, November 2006, p. 1181-1184, Vol. 13, No. 11
1071-412X/06/$08.00+0     doi:10.1128/CVI.00203-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

National Serosurvey of Cytomegalovirus in Australia{triangledown}

Holly Seale,1* C. Raina MacIntyre,2 Heather F. Gidding,3 J. L. Backhouse,3 Dominic E. Dwyer,3 and Lyn Gilbert3

National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), The Children's Hospital at Westmead and the University of Sydney, Sydney, New South Wales, Australia,1 School of Public Health, University of Sydney, Sydney, New South Wales, Australia,2 Centre for Infectious Diseases and Microbiology (CIDM)-Public Health, Institute of Clinical Pathology and Medical Research, Westmead Hospital, Westmead, New South Wales, Australia3

Received 29 May 2006/ Returned for modification 11 July 2006/ Accepted 29 August 2006

In anticipation of the development of a vaccine against cytomegalovirus (CMV), we conducted a large, nationally representative serosurvey to examine the seroprevalence of CMV in Australia. Sera were collected opportunistically from laboratories around Australia. Age- and gender-representative samples were tested for CMV antibody. The population-weighted rate of CMV seropositivity in subjects between 1 and 59 years of age was 57% (95% confidence interval, 55.2 to 58.6%). An association between CMV seroprevalence and increasing age was recognized; however, little overall difference in seroprevalence between the sexes was found. The finding that high levels of CMV exposure occur in the first few years of life suggests that for a universal vaccination program to have maximal impact, the vaccine would need to be delivered to infants and have a long duration of protective efficacy. This is the first national serosurvey looking at cytomegalovirus in the Australian community. This study provides valuable information that can be used to examine the incidence of infection in the community and help focus the administration of a future CMV vaccine to appropriate target populations.

* Corresponding author. Mailing address: National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), Locked Bag 4001, Westmead, NSW 2145, Australia. Phone: (612) 9845 1421. Fax: (612) 9845 1418. E-mail: hsea3454{at}mail.usyd.edu.au.

{triangledown} Published ahead of print on 6 September 2006.

Clinical and Vaccine Immunology, November 2006, p. 1181-1184, Vol. 13, No. 11
1071-412X/06/$08.00+0     doi:10.1128/CVI.00203-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Fang, F.-Q., Fan, Q.-S., Yang, Z.-J., Peng, Y.-B., Zhang, L., Mao, K.-Z., Zhang, Y., Ji, Y.-H. (2009). Incidence of Cytomegalovirus Infection in Shanghai, China. CVI 16: 1700-1703 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»